Bailard’s BioXcel Therapeutics BTAI Stock Holding History

Bailard’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,875	Closed	-$1.4M	–	727
2021 Q3	$1.4M	Buy	+2,875	New	+$1.26M	0.05%	231

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bailard's BTAI Position: Q4 2021 in Review

Bailard sold out of BioXcel Therapeutics (BTAI) in Q4 2021, closing a stake of 2,875 shares — an estimated $1.4M sold.

Bailard first reported a position in BTAI in Q3 2021 and held it in 1 quarter. The position peaked at $1.4M in Q3 2021. 93 funds tracked by Wall St. Rank hold BTAI as of Q4 2021.

Bailard reported no remaining BioXcel Therapeutics position as of Q4 2021 after selling out during the quarter.
Bailard sold 2,875 BioXcel Therapeutics shares in Q4 2021, an estimated $1.4M.
Bailard first reported a position in BioXcel Therapeutics in Q3 2021 and held it in 1 quarter.
Bailard's BioXcel Therapeutics position peaked at $1.4M in Q3 2021.
93 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2021.

Based on Bailard's 13F filing for Q4 2021, filed 10 Feb 2022.